ArticleScientific reports2026
Nationwide survey of Japanese Physicians on Kampo medicine use in frailty care.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is a multidimensional, progressive syndrome that has become a priority for early intervention in aging societies. Kampo medicine, a traditional multi-herbal therapy, may offer an additional treatment option. However, limited evidence exists on how physicians perceive and apply it in frailty care. We conducted a nationwide web-based survey of physicians in Japan (n = 8,351) to evaluate frailty recognition, Kampo prescription patterns, and treatment assessments. Overall, 46.4% reported diagnosing frailty. Clinic-based physicians prescribed Kampo medicine more often than hospital-based physicians (14.1% vs. 10.5%; P < 0.001) and most commonly for appetite loss, malnutrition, and sarcopenia. They also assessed effects earlier (within 2 weeks: 19.5% vs. 13.5%; P = 0.002). In adjusted analyses, Kampo prescribing was more likely among clinic-based physicians and those in internal medicine or surgery, and less likely in larger facilities (≥ 200 beds). Clinic-based physicians were also more likely to rate Kampo as highly effective. In contrast, physicians aged ≥ 60 years prescribed Kampo less often but were more likely to choose it for their own frailty management. This first nationwide study shows that practice setting, specialty, facility size, and physician age shape frailty care and Kampo use in Japan, highlighting the need for further evidence and education to guide integrative care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.